Information:
Error:
Keywords
- Gynecology (76)
- Medical Oncology (64)
- Fallopian Tube Neoplasms (34)
- Eligibility Determination (29)
- Peritoneal Neoplasms (27)
- Vital Signs (27)
- Laboratories (15)
- Hematology (13)
- Office Visits (13)
- Drugs, Investigational (12)
- Clinical Trial, Phase II (8)
- Drug trial (6)
- General Surgery (5)
- Tumor Markers, Biological (5)
- Clinical Chemistry Tests (5)
- Adverse event (5)
- Biological Markers (4)
- On-Study Form (4)
- Disease Status (4)
- Physical Examination (3)
- Quality of Life (3)
- Concomitant Medication (3)
- End of Study (3)
- Drug Therapy (3)
- Pathology (3)
- Uterine Neoplasms (2)
- Chemotherapy, Adjuvant (2)
- Clinical Trial, Phase III (2)
- Topotecan (2)
- Treatment Form (2)
- Off-Treatment (2)
- Non Small Cell Lung Cancer (2)
- Cisplatin (2)
- Death (2)
- Follow-Up Studies (2)
- Medical History Taking (2)
- Pharmacogenetics (1)
- Pregnancy (1)
- Prostatic Neoplasms (1)
- Radiotherapy (1)
- Research Personnel (1)
- Sarcoma (1)
- Survival (1)
- Colorectal Neoplasms (1)
- Pulmonary Medicine (1)
- Comment (1)
- Endometrial Neoplasms (1)
- Biopsy (1)
- Sex Cord-Gonadal Stromal Tumors (1)
- Tomography, Spiral Computed (1)
- Carcinoma (1)
- Carcinoma, Squamous Cell (1)
- Transcriptome (1)
- Clinical Laboratory Services (1)
- Registration (1)
- Baseline (1)
- Specimen (1)
- Trial screening (1)
- Electrocardiogram (ECG) (1)
- Demography (1)
- Gastroenterology (1)
- Giant Cell Tumors (1)
- Head and Neck Neoplasms (1)
- Histology (1)
- Informed Consent (1)
- Kidney Failure, Chronic (1)
- Neoplasms by Site (1)
Table of contents
Selected data models
You must log in to select data models for download or further analysis.
113 Search results.
Itemgroups: Header,Inclusion Criteria,Exclusion Criteria
Itemgroups: Physical Well-Being,SOCIAL/FAMILY WELL-BEING,EMOTIONAL WELL_BEING,FUNCTIONAL WELL-BEING,Additional Concerns,CCRR MODULE
Itemgroups: Administrative documentation,Assessment Date,Demography,Menopausal Status,Medical History,Symptoms, Study Start Date,Concomitant Agent,ECOG performance status,Personal history of malignant neoplasm, unspecified,Ovarian Carcinoma, Histology,Ovarian Carcinoma, Operative Surgical Procedures,Tumor stage,Tumor Markers,Physical Examination, Lower abdomen,X-Ray Computed Tomography,Plain x-ray,Electrocardiography,Questionnaires, Quality of life,Receptor
Itemgroups: Header,Eligibility Question,Demography,Physical examination,Disease Characteristics,Metastatic Disease Site,local laboratory,Residual toxicities related to previous therapy for cancer,Residual toxicities,Cancer related current medical conditions,Medical Conditions,non-cancer related medical conditions,Medical Conditions,Prior anti-cancer therapy,Prior anti-cancer therapy - medication,Prior anti-cancer therapy - radiotherapy,Vital signs,ECOG Performance Status Scale,12 LEAD ECG,12-lead ECG Abnormalities,Local Laboratory - Haematology,Local Laboratory - Clinical Chemistry,Urinalysis,Electronically transferred laboratory data
Itemgroups: Administrative data,Primary,Histology Type,Histologic Grade,Specimens,Secondary
Itemgroups: Administrative documentation,Follow-up, Month,Clinical Trials, Result,X-Ray Computed Tomography,Tumor Markers,follow-up visit date,Response to treatment, Evaluation,Therapeutic procedure, Other,Investigator Signature
Itemgroups: Survival Information - Month of Report,Survival Information - Review of disease status,Survival Information - Outcome,Form D,Termination Record,Termination Record - Review of Disease Status,Termination Record - Best Overall Response,Termination Record - Study Conclusion,Termination Record - Investigator Signature
Itemgroups: Administrative,Are there any non-serious adverse events to report?,Non-Serious adverse Events,Serious Adverse Event #1,Serious Adverse Event #1 - Relevant Laboratory Data,Serious Adverse Event #1 - Signature,Prior and Concomitant Medications,Prior and Concomitant Medications
Itemgroups: Administrative,Eligibility,Vital Signs,Administration of Study Medications,Topotecan Administration,Gemcitabine Administration
Itemgroups: Administrative,Day 8 Vital Signs,Hematology,Hematology,Day 8 Administration of Study Medications,Topotecan Administration,Gemicitabine Administration
Itemgroups: Administrative,Day 15 Vital Signs,Hematology,Hematology,Day 15 Administration of Study Medications,Topotecan Administration,Gemcitabine Administration
Itemgroups: Administrative,Vital Signs,Tumor Marker (CA-125),Laboratory Tests - Haematology,Laboratory Tests - Haematology ,Laboratory Tests - Chemistry,Laboratory Tests - Chemistry ,Lesion Assessment,Lesion Assessment Record